Your browser doesn't support javascript.
loading
Asprosin: its function as a novel endocrine factor in metabolic-related diseases.
Zhang, Y; Yang, P; Zhang, X; Liu, S; Lou, K.
Afiliação
  • Zhang Y; Department of Endocrinology, Shandong Rongjun General Hospital, 23 Jiefang Road, Jinan, 250013, Shandong Province, China.
  • Yang P; Department of Endocrinology, Shandong Rongjun General Hospital, 23 Jiefang Road, Jinan, 250013, Shandong Province, China.
  • Zhang X; Department of Cardiology, Shandong Rongjun General Hospital, Jinan, 250013, China.
  • Liu S; Department of Endocrinology, Shandong Rongjun General Hospital, 23 Jiefang Road, Jinan, 250013, Shandong Province, China. lsd008@126.com.
  • Lou K; Department of Endocrinology, Jinan Central Hospital Affiliated to Shandong First Medical University, 105 Jiefang Road, Jinan, 250013, Shandong Province, China. loukai2014@163.com.
J Endocrinol Invest ; 47(8): 1839-1850, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38568373
ABSTRACT
BACKGROUND AND

PURPOSE:

Asprosin was discovered as a new endocrine hormone originating from fibrillin-1 cleavage that plays a crucial role in various metabolic-related diseases, such as obesity, nonalcoholic fatty liver disease (NAFLD), diabetes, polycystic ovary syndrome (PCOS), and cardiovascular diseases. The purpose of this review is to describe the recent advancements of asprosin.

METHOD:

Narrative review.

RESULT:

This comprehensive review explores its tissue-specific functions, focusing on white adipose tissue, liver, hypothalamus, testis, ovary, heart, pancreas, skeletal muscle, and kidney.

CONCLUSION:

Asprosin is a multifaceted protein with tissue-specific roles in various physiological and pathological processes. Further research is needed to fully understand the mechanisms and potential of asprosin as a therapeutic target. These insights could provide new directions for treatments targeting metabolic-related diseases.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilina-1 / Doenças Metabólicas Limite: Animals / Humans Idioma: En Revista: J Endocrinol Invest Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrilina-1 / Doenças Metabólicas Limite: Animals / Humans Idioma: En Revista: J Endocrinol Invest Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China